C-YDUCGenflow Biosciences
SIRT6 gene therapy, AAV delivery, longevity therapeutics
editinggene therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-YDUC
C-YDUCC-YDUCSIRT6 gene therapy, AAV delivery, longevity therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Genflow Biosciences SIRT6 gene therapy, AAV delivery, longevity therapeutics
Genflow Biosciences is a longevity biotechnology company founded in 2020 with R&D facilities in Belgium and a US office in Cambridge, MA. Its lead compound, GF-1002, delivers a centenarian variant of the SIRT6 gene using an adeno-associated viral vector. The company is developing programs for humans and dogs, including an aged-dog SLAB study and preparation for a Phase I/II clinical trial in advanced MASH.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Genflow Biosciences — Early mechanism · Lower middle. Derived deterministically from 10 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (8 programs at preclinical).…
Source: Deterministic